GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
O

Oncolytics Biotech ONCY · USD

Health Care · US listing · 🇺🇸 United States

Compare

0.39

-11.29%

Close of 19 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

Price performance

Chart by TradingView, with its own licensed prices

Oncolytics Biotech — daily ONCY Delayed
Market value
$46.6m
Last close × shares
Volume
1.7m
Shares, 19 Nov 2026

About Oncolytics Biotech

From its filings with the US Securities and Exchange Commission

SEC filings

Oncolytics Biotech is based in San Diego, California and is incorporated in Nevada. Its shares trade on Nasdaq under the ticker ONCY. The SEC classifies its business as pharmaceutical preparations. In the fiscal year to 31 December 2025, it reported a net loss of $28.8m. At that date it held total assets of $7.6m and shareholders' equity of −$3.8m.

In its own words

We are a clinical-stage biopharmaceutical company developing pelareorep, a well-tolerated intravenously delivered immunotherapeutic agent that selectively replicates in RAS-mutated tumors and activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments.

Pelareorep is a proprietary isolate of reovirus, a naturally occurring, non-pathogenic double-stranded RNA (“dsRNA”) virus commonly found in environmental waters. Pelareorep has shown promising results in changing the tumor microenvironment (“TME”). This creates a more immunologically favorable TME, making the tumor more susceptible to various treatment combinations. These treatments include chemotherapies, checkpoint inhibitors (“CPIs”), and other immuno-oncology approaches such as CAR T therapies, bispecific antibodies, and RAS or CDK4/6 inhibitors. Pelareorep induces a new army of tumor-reactive T cells, helps these cells to infiltrate the tumor through an inflammatory process, and upregulates the expression of PD-1/PD-L1. By priming the immune system with pelareorep, we believe we can increase the proportion of patients who respond to various cancer treatments, including immunotherapies, especially in cancers where existing treatment regimens have failed or provided limited benefit.

Quoted from its 10-K, filed 30 Mar 2026. Read the filing on SEC.gov ↗

More about Oncolytics Biotech →

Latest on Oncolytics Biotech

Our reporting

We have not reported on Oncolytics Biotech yet.

Next results

26 Feb 2027

Due on 26 Feb 2027. Analysts expect earnings of -0.06 a share.

Other Health Care listings

Scenario calculator

Try your own numbers. This is arithmetic, not a forecast.

Interactive

Gain or loss

—

Return

—

Leaves out fees, taxes and financing.

Frequently asked questions

What is Oncolytics Biotech's ticker?

Oncolytics Biotech trades as ONCY on its US listing, under ISIN US68237V1035.

What was Oncolytics Biotech's last closing price?

0.39 on 19 Nov 2026. The figure is in USD and is never converted.

When does Oncolytics Biotech next report results?

Results are expected on 11 Nov 2026, according to our data supplier.

Sources and methodology

Chart
TradingView
Close and company data
SEC filings and our data supplier
News
Our reporting

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.